EIKN (NASDAQ:EIKN) Coverage Initiated by Analysts at Bank of America

Investment analysts at Bank of America started coverage on shares of EIKN (NASDAQ:EIKN) in a research report issued to clients and investors on Monday,Benzinga reports. The firm set a “buy” rating and a $34.00 price target on the stock. Bank of America‘s price objective would suggest a potential upside of 146.73% from the company’s current price.

A number of other research analysts have also commented on the company. Wedbush began coverage on EIKN in a report on Thursday. They set an “underperform” rating and a $7.00 price target for the company. Wall Street Zen upgraded shares of EIKN to a “hold” rating in a research note on Monday, February 16th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, EIKN presently has an average rating of “Moderate Buy” and a consensus price target of $24.75.

EIKN Price Performance

EIKN stock opened at $13.78 on Monday. EIKN has a 52 week low of $13.28 and a 52 week high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.